Therapeutic Vaccines and Nucleic Acid Drugs for Cardiovascular Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
To combat the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel vaccine modalities, such as messenger RNA vaccines, were rapidly developed and have shown high efficacy. This new vaccine technology, underpinned by intensive immunological analysis, is now being applied to the production of other vaccines. For over 10 years, we have been developing therapeutic vaccines for non-infectious diseases. The epitope vaccine approach, which combines a B-cell epitope with exogenous T-cell epitopes presented through major histocompatibility complex molecules, has been proposed to induce antibody production. This vaccine type is designed to efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. If therapeutic vaccines become established as treatment options for conditions such as hypertension or dyslipidemia, their administration—potentially only a few times per year—could replace the need for daily medication. Nucleic acid drugs, including small interfering RNA and antisense oligonucleotides, have recently received attention as long-term agonists, similar to vaccines. Therefore, therapeutic vaccines or nucleic acid drugs could represent a novel strategy for controlling the progression of cardiovascular diseases. It is hoped that the accumulation of immunological findings and advances in vaccine technology will provide valuable insights into the development of vaccines for treating cardiovascular diseases.
Abstract
To combat the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), novel vaccine modalities, such as messenger RNA vaccines, were rapidly developed and have shown high efficacy. This new vaccine technology, underpinned by intensive immunological analysis, is now being applied to the production of other vaccines. For over 10 years, we have been developing therapeutic vaccines for non-infectious diseases. The epitope vaccine approach, which combines a B-cell epitope with exogenous T-cell epitopes presented through major histocompatibility complex molecules, has been proposed to induce antibody production. This vaccine type is designed to efficiently induce a blocking antibody response against the self-antigen without activating cytotoxic T cells. If therapeutic vaccines become established as treatment options for conditions such as hypertension or dyslipidemia, their administration—potentially only a few times per year—could replace the need for daily medication. Nucleic acid drugs, including small interfering RNA and antisense oligonucleotides, have recently received attention as long-term agonists, similar to vaccines. Therefore, therapeutic vaccines or nucleic acid drugs could represent a novel strategy for controlling the progression of cardiovascular diseases. It is hoped that the accumulation of immunological findings and advances in vaccine technology will provide valuable insights into the development of vaccines for treating cardiovascular diseases.
참고문헌 (44)
- Nakagami H, "Development of COVID-19 vaccines utilizing gene therapy technology", Int Immunol, 33, pp.521~527 (2021)
- Corbett KS, "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", Nature, 586, pp.567~571 (2020)
- Gao Q, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369, pp.77~81 (2020)
- Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
- Nakagami H, "Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases", J Cardiol, 70, pp.201~205 (2017)
- Yoshida S, "The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice", Nat Commun, 11, pp.2482~ (2020)
- Pang Z, "Therapeutic vaccine against DPP4 improves glucose metabolism in mice", Proc Natl Acad Sci U S A, 111, pp.E1256~ (2014)
- Kitsuka T, "A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction", Sci Rep, 12, pp.6923~ (2022)
- Suda M, "Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice", Nat Aging, 1, pp.1117~1126 (2021)
- Wardemann H, "Predominant autoantibody production by early human B cell precursors", Science, 301, pp.1374~1377 (2003)
- Harris JR, "Keyhole limpet hemocyanin(KLH) : a biomedical review", Micron, 30, pp.597~623 (1999)
- Crotty S, "Follicular helper CD4 T cells(TFH)", Annu Rev Immunol, 29, pp.621~663 (2011)
- Zhang J, "Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals", Nat Microbiol, 6, pp.51~58 (2021)
- Tenma A, "AJP001, a novel helper T-cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine", FASEB Bioadv, 1, pp.760~772 (2019)
- Nakamaru R, "A novel angiotensin II peptide vaccine without an adjuvant in mice", J Hypertens, 39, pp.181~189 (2021)
- Ferrer I, "Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease", Brain Pathol, 14, pp.11~20 (2004)
- Ambühl PM, "A vaccine for hypertension based on virus-like particles : preclinical efficacy and phase I safety and immunogenicity", J Hypertens, 25, pp.63~72 (2007)
- Brown MJ, "Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine(PMD3117)in hypertensive subjects", Clin Sci(Lond), 107, pp.167~173 (2004)
- Tissot AC, "Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure : a double-blind, randomised, placebo-controlled phase IIa study", Lancet, 371, pp.821~827 (2008)
- Nakagami F, "Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice", PLoS One, 8, pp.e60493~ (2013)
- Koriyama H, "Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats", Hypertension, 66, pp.167~174 (2015)
- Watanabe R, "A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction", Sci Rep, 7, pp.43920~ (2017)
- Wakayama K, "Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress", Stroke, 48, pp.1362~1368 (2017)
- Nakagami H, "Brief report on a phase I", IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension, 2022, pp.45, 61~65
- Fredrikson GN, "Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease", Arterioscler Thromb Vasc Biol, 23, pp.872~878 (2003)
- Fredrikson GN, "Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression", Autoimmunity, 38, pp.171~179 (2005)
- Rittershaus CW, "Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis", Arterioscler Thromb Vasc Biol, 20, pp.2106~2112 (2000)
- Davidson MH, "The safety and immunogenicity of a CETP vaccine in healthy adults", Atherosclerosis, 169, pp.113~120 (2003)
- Catapano AL, "The safety of therapeutic monoclonal antibodies : implications for cardiovascular disease and targeting the PCSK9 pathway", Atherosclerosis, 228, pp.18~28 (2013)
- Koren MJ, "Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin", kexin type 9 as monotherapy in patients with hypercholesterolaemia(MENDEL) : a randomised, double-blind, placebo-controlled, phase 2 study, 2012, pp.380, 1995~2006
- Kazi DS, "Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease", JAMA, 316, pp.743~753 (2016)
- Kawakami R, "Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin", kexin type 9(PCSK9)epitope in mice, 2018, pp.13, e0191895~
- Fukami H, "Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia", Cell Rep Med, 2, pp.100446~ (2021)
- Nakagami H, "Challenges in the development of novel therapies, vaccines and siRNAs for the treatment of hypertension", Hypertens Res, 46, pp.1812~1815 (2023)
- Ranasinghe P, "Small interfering RNA : Discovery, pharmacology and clinical development-an introductory review", Br J Pharmacol, 180, pp.2697~2720 (2023)
- Sheu-Gruttadauria J, "Structural foundations of RNA silencing by Argonaute", J Mol Biol, 429, pp.2619~2639 (2017)
- Setten RL, "The current state and future directions of RNAi-based therapeutics", Nat Rev Drug Discov, 18, pp.421~446 (2019)
- Jinek M, "A three-dimensional view of the molecular machinery of RNA interference", Nature, 457, pp.405~412 (2009)
- Ray KK, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol", N Engl J Med, 376, pp.1430~1440 (2017)
- Springer AD, "GalNAc-siRNA conjugates : leading the way for delivery of RNAi therapeutics", Nucleic Acid Ther, 28, pp.109~118 (2018)
- Raal FJ, "Evinacumab for homozygous familial hypercholesterolemia", N Engl J Med, 383, pp.711~720 (2020)
- Desai AS, "Zilebesiran, an RNA interference therapeutic agent for hypertension", N Engl J Med, 389, pp.228~238 (2023)
- Kawano T, "Therapeutic vaccine against S100A9(S100 calcium-binding protein A9)inhibits thrombosis without increasing the risk of bleeding in ischemic stroke in mice", Hypertension, 72, pp.1355~1364 (2018)
- Bussian TJ, "Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline", Nature, 562, pp.578~582 (2018)